Abbott has officially opened its new state-of-the-art biologics manufacturing facility in PR to support the long-term supply Humira and other future biologics. The facility, Abbott Biotechnology Limited (ABL), received FDA approval in February to commercially produce Humira for the U.S. market. This new plant has significantly more production capacity than Abbott’s Bioresearch Center (ABC) in Worcester, MA, where the drug was previously manufactured. “This new facility is a key milestone...